Loading institutional data...
Loading institutional data...
Held by 273 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $25.93 today, the market must believe free cash flow compounds -2.1%/yr for a decade (off $180M normalized FCF).
The market's -2.1% is more optimistic than its 9-yr track record.
2-stage DCF · 0.08B shares · net debt -$375M
mean 19.0% · volatility σ 85% · implied rate exceeded in 5/9 yrs
Central path = implied -2.1%/yr growth; shaded band = ±1σ (85%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| MD | $2.2B | 13.4× | 7.7× | 1.1× | -4.9% | — | 8.6% | 19.1% | 19.1% | — | 273 |
Peers = companies sharing MD's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $87M buybacks = $87M returned on $253M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 19%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $375M covers the $20M due within a year 18.8× over. Scheduled principal only (excludes interest & revolver draws). As of 2016-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-18
Nothing notable to watch.
Where each multiple sits in its own 14-yr range · 35th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 82.1× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| SG&A | 13.5 | 13.7 | 14.4 | 13.8 | 11.7 | 11.4 | 11.8 | 12.6 |
| Operating Income | 14.4 | 9.7 | 5.7 | 10.6 | 8.8 | 0.4 | -3.4 | 10.9 |
| Income Tax | 2.6 | 0.9 | 1.0 | 1.4 | 1.0 | 0.6 | -0.1 | 2.7 |
| Net Income | 15.6 | -84.2 | -45.9 | 6.9 | 3.4 | -3.0 | -4.9 | 8.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on MD: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.91B 100.0% | $2.01B 100.0% | $1.99B 100.0% | $1.97B 100.0% | $1.91B 100.0% | $1.73B 100.0% | $1.78B 100.0% | $1.72B 100.0% | $3.25B 100.0% | $3.18B 100.0% |
| Selling, General & Admin | $240.8M 12.6% | $238.4M 11.8% | $227.5M 11.4% | $231.4M 11.7% | $263.4M 13.8% | $248.9M 14.4% | $244.5M 13.7% | $232.2M 13.5% | $385.9M 11.9% | $372.6M 11.7% |
| Total Operating Expenses | $1.71B 89.1% | $2.08B 103.4% | $1.99B 99.6% | $1.80B 91.2% | $1.71B 89.4% | $1.64B 94.3% | $1.61B 90.3% | $1.47B 85.6% | $2.80B 86.0% | $2.61B 82.0% |
| Operating Income | $208.8M 10.9% | -$68.7M -3.4% | $7.3M 0.4% | $172.7M 8.8% | $202.9M 10.6% | $98.1M 5.7% | $171.8M 9.7% | $248.4M 14.4% | $454.9M 14.0% | $571.7M 18.0% |
| Interest Expense | $36.0M 1.9% | $40.7M 2.0% | $42.1M 2.1% | $39.7M 2.0% | $68.7M 3.6% | $110.5M 6.4% | $118.9M 6.7% | $92.9M 5.4% | $74.6M 2.3% | $63.1M 2.0% |
| Other Income (Expense), net | $7.6M 0.4% | -$32.6M -1.6% | -$55.7M -2.8% | -$91.3M -4.6% | -$67.7M -3.5% | -$91.0M -5.2% | -$113.0M -6.3% | -$82.2M -4.8% | -$69.2M -2.1% | -$57.9M -1.8% |
| Pretax Income | $216.4M 11.3% | -$101.3M -5.0% | -$48.4M -2.4% | $81.4M 4.1% | $135.2M 7.1% | $7.1M 0.4% | $58.8M 3.3% | $166.2M 9.6% | $385.7M 11.9% | $513.8M 16.1% |
| Income Tax Expense | $51.0M 2.7% | -$2.3M -0.1% | $12.0M 0.6% | $18.8M 1.0% | $27.2M 1.4% | $16.7M 1.0% | $16.6M 0.9% | $44.7M 2.6% | $80.2M 2.5% | $189.2M 5.9% |
| Net Income | $165.4M 8.6% | -$99.1M -4.9% | -$60.4M -3.0% | $66.3M 3.4% | $131.0M 6.9% | -$796.5M -45.9% | -$1.50B -84.2% | $268.6M 15.6% | $320.4M 9.8% | $324.9M 10.2% |
| Per Share | ||||||||||
| EPS (Basic) | $1.97 | $-1.19 | $-0.73 | $0.79 | $1.54 | $-9.55 | $-17.94 | $2.95 | $3.47 | $3.52 |
| EPS (Diluted) | $1.94 | $-1.19 | $-0.73 | $0.79 | $1.53 | $-9.55 | $-17.83 | $2.93 | $3.45 | $3.49 |
| Weighted Avg Shares (Basic) | 84.4M | 83.3M | 82.2M | 83.5M | 84.8M | 83.4M | 83.5M | 91.1M | 92.4M | 92.4M |
| Weighted Avg Shares (Diluted) | 85.4M | 83.3M | 82.2M | 84.1M | 85.8M | 83.4M | 84.0M | 91.6M | 93.0M | 93.1M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.